Roslyn Tedja, Ph.D. is currently an Associate Research Scientist in the Department of Obstetrics, Gynecology, and Reproductive Sciences. She received her Ph.D. in 2012 from School of Chemical Engineering, University of New South Wales, Sydney, Australia. She joined a Cancer Therapeutic Company, EnGeneIc Pty. Ltd., Sydney, Australia as postdoctoral fellow in 2012. She then joined a Plasma Therapeutic Company, Prime Biologics, Sydney, Australia in 2014 as a Senior Research and Development Scientist. She came to Yale University in 2015 as an Associate Research Scientist in Dr. Gil Mor’s laboratory, where she uncovered novel pathways facilitating Epithelial-to-Mesenchymal Transition (EMT) in epithelial ovarian cancer stem cells. More recently, she focused on developing nanoparticle platform for minimizing metastasis formation. Additionally, she also developed trans-immunization to prevent recurrence in an ovarian cancer animal model.
Education & Training
|PhD||University of New South Wales, Chemical Engineering (Nanotechnology) (2012)|
|BSc (Hon)||University of New South Wales, Biotechnology (2008)|
|Senior Development Scientist||PrIME Biologics Pty. Ltd.|
|Postdoctoral Research||Cancer Therapeutic EnGene IC|